Synchronous Medullary Carcinoma, Hurthle Cell Carcinoma and Parathyroid Adenoma: A Unique Case Report and Literature Review
Presently described is the case of a 68-year-old female patient who presented at a general surgery clinic with the complaint of swelling in the throat. Medullary carcinoma, Hurthle cell carcinoma, and parathyroid adenoma were detected. The patient underwent surgery and was followed-up with vitamin D and 1-thyroxine replacement therapy.
1.Biscolla RP, Ugolini C, Sculli M, Bottici V, Castagna MG, Romei C, et al. Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid 2004;14:946–52. [CrossRef ]
2. Dionigi G, Castano P, Bertolini V, Boni L, Rovera F, Tanda ML, et al. Simultaneous medullary and papillary thyroid cancer: two case reports. J Med Case Rep 2007;1:133. [CrossRef ]
3. Machens A, Dralle H. Simultaneous medullary and papillary thyroid cancer: a novel entity? Ann Surg Oncol 2012;19:37–44.
4. Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1996;44:249–57. [CrossRef ]
5. Cheung L, Howlett D, El Teraifi H, Kirkland P. Association of synchronous medullary and papillary thyroid carcinomas with primary hyperparathyroidism: first case report and literature review. J Laryngol Otol 2014;128:565–8. [CrossRef ]
6. Ciampi R, Romei C, Pieruzzi L, Tacito A, Molinaro E, Agate L, et al. 17. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland. J Endocrinol Invest 2017;40:55–62. [CrossRef ]
7. Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 2013;23:50–7. [CrossRef ]
8. Komminoth P. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications. Virchows Arch 1997;431:1–9.
9. Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 2011;96:E863–8. [CrossRef ]
10. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al; Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25:567–610. [CrossRef ]
11. Behrand M, von Wasielewski R, Brabant G. Simultaneous medullary and papillary microcarcinoma of thyroid in a patient with secondary hyperparathyroidism. Endocr Pathol 2002;13:65–73. [CrossRef ]